ProfileGDS5678 / 1425899_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 82% 81% 83% 82% 83% 82% 85% 82% 82% 82% 81% 82% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4367279
GSM967853U87-EV human glioblastoma xenograft - Control 26.0158882
GSM967854U87-EV human glioblastoma xenograft - Control 35.742781
GSM967855U87-EV human glioblastoma xenograft - Control 46.2142983
GSM967856U87-EV human glioblastoma xenograft - Control 55.9220582
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9267283
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8004882
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3233485
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8895582
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.928182
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8620982
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8140981
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9871782
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7702481